Antibiotic-Resistant Infections: Risks, Costs, Pg13

Key Highlights:

• A major study in India found that infections caused by antibiotic-resistant bacteria are more fatal and expensive to treat than drug-susceptible infections.
• The study, conducted by the Indian Council of Medical Research (ICMR), focused on carbapenem-resistant infections.
• It covered 159,336 hospitalised patients across 20 tertiary-care hospitals from April 2022 to April 2025.
• Approximately 61.1% of patients had infections resistant to carbapenems, a powerful class of antibiotics.
• The research highlighted significantly higher mortality rates and treatment costs for resistant infections across four major bacteria.

AMR.jpg

Detailed Insights:

• Carbapenem resistance poses a significant threat to patient survival, particularly in severe and bloodstream infections.
• Resistant infections were linked to increased deaths, longer hospital stays, and higher antibiotic expenditures.
• For E. coli, carbapenem-resistant infections resulted in a 24.4% mortality rate compared to 17.3% for susceptible strains.
• The average antibiotic cost for resistant E. coli infections was approximately Rs 39,846 per patient, nearly double that of susceptible infections.
• Over 85% of bloodstream infections studied were healthcare-associated, underscoring the need for robust infection prevention and control in hospitals.
• The study's cost estimates are conservative, as they only included antibiotics available under the Jan Aushadhi scheme and excluded other significant hospital costs.
• Concerns include healthcare-associated transmission, the use of invasive devices, recent surgeries, and gaps in infection prevention and timely diagnosis.
• Hospitals require timely diagnostics to identify resistant bacteria, enabling the use of targeted antibiotics instead of broad-spectrum drugs.
• An integrated surveillance system connecting laboratory results with patient outcomes, mortality, and treatment is crucial.
• Effective Antimicrobial Resistance (AMR) management requires preventing infections, early diagnosis, and preserving the efficacy of existing antibiotics.

Key Concepts Involved:

• Antibiotic Resistance: The ability of bacteria to survive or grow in the presence of antibiotics designed to kill them.
• Carbapenems: A class of highly effective, broad-spectrum beta-lactam antibiotics used for severe bacterial infections.
• Antimicrobial Resistance (AMR): A global health and development threat where microorganisms evolve to resist antimicrobial drugs, making infections harder to treat.
• Indian Council of Medical Research (ICMR): India's apex body for the formulation, coordination, and promotion of biomedical research.